ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody

References

• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244 - 279
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Scheurich P, Pfizenmaier K. Antagonists of TNF action—clinical experience and new developments. Expert Opin Drug Discov 2009; 4:279 - 292
   PubMed Web of Science ®Google Scholar
• Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:889 - 894
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275 - 2285
   PubMed Web of Science ®Google Scholar
• Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20:757 - 790
   PubMed Web of Science ®Google Scholar
• Wallis RS. Tumour necrosis factor antagonists: structure, function and tuberculosis risks. Lancet Infect Dis 2008; 8:601 - 611
   PubMed Web of Science ®Google Scholar
• Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487 - 501
   PubMed Web of Science ®Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10:45 - 65
   PubMed Web of Science ®Google Scholar
• Wallach D, Kovalenko A. 12th international TNF conference: the good, the bad and the scientists. Cytokine Growth Factor Rev 2009; 20:259 - 269
   PubMed Web of Science ®Google Scholar
• TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999; 53:457 - 465 Anonymous
   PubMed Web of Science ®Google Scholar
• Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNFalpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4:1116 - 1122
   PubMed Web of Science ®Google Scholar
• Shibata H, Yoshioka Y, Ohkawa A, Minowa K, Mukai Y, Abe Y, et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem 2008; 283:998 - 1007
   PubMed Web of Science ®Google Scholar
• Shibata H, Yoshioka Y, Ohkawa A, Abe Y, Nomura T, Mukai Y, et al. The therapeutic effect of TNFR1-selective antagonistic mutant TNFalpha in murine hepatitis models. Cytokine 2008; 44:229 - 233
   PubMed Web of Science ®Google Scholar
• Shibata H, Yoshioka Y, Abe Y, Ohkawa A, Nomura T, Minowa K, et al. The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials 2009; 30:6638 - 6647
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 2007; 179:1872 - 1883
   PubMed Web of Science ®Google Scholar
• Olleros ML, Vesin D, Lambou AF, Janssens JP, Ryffel B, Rose S, et al. Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guerin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J Infect Dis 2009; 199:1053 - 1063
   PubMed Web of Science ®Google Scholar
• Thoma B, Grell M, Pfizenmaier K, Scheurich P. Identification of a 60 kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J Exp Med 1990; 172:1019 - 1023
   PubMed Web of Science ®Google Scholar
• Kruppa G, Thoma B, Machleidt T, Wiegmann K, Kronke M. Inhibition of tumor necrosis factor (TNF)-mediated NFkappaB activation by selective blockade of the human 55 kDa TNF receptor. J Immunol 1992; 148:3152 - 3157
   PubMed Web of Science ®Google Scholar
• Moosmayer D, Dubel S, Brocks B, Watzka H, Hampp C, Scheurich P, et al. A single-chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity. Ther Immunol 1995; 2:31 - 40
   PubMedGoogle Scholar
• Kontermann RE, Munkel S, Neumeyer J, Muller D, Branschadel M, Scheurich P, et al. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. J Immunother 2008; 31:225 - 234
   PubMed Web of Science ®Google Scholar
• Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999; 29:2613 - 2624
   PubMed Web of Science ®Google Scholar
• Krippner-Heidenreich A, Tubing F, Bryde S, Willi S, Zimmermann G, Scheurich P. Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction. J Biol Chem 2002; 277:44155 - 44163
   PubMed Web of Science ®Google Scholar
• Terato K, Arai H, Shimozuru Y, Fukuda T, Tanaka H, Watanabe H, et al. Sex-linked differences in susceptibility of cynomolgus monkeys to type II collagen-induced arthritis. Evidence that epitope-specific immune suppression is involved in the regulation of type II collagen autoantibody formation. Arthritis Rheum 1989; 32:748 - 758
   PubMed Web of Science ®Google Scholar
• Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFbeta complex: implications for TNF receptor activation. Cell 1993; 73:431 - 445
   PubMed Web of Science ®Google Scholar
• Branschadel M, Aird A, Zappe A, Tietz C, Krippner-Heidenreich A, Scheurich P. Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: conformational stabilization of CRD2 and control of receptor responsiveness. Cell Signal 2009; 22:404 - 414
   Web of Science ®Google Scholar
• Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288:2351 - 2354
   PubMed Web of Science ®Google Scholar
• Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000; 288:2354 - 2357
   PubMed Web of Science ®Google Scholar
• Boschert V, Krippner-Heidenreich A, Branschadel M, Tepperink J, Aird A, Scheurich P. Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2. Cell Signal 2010; 22:1088 - 1096
   PubMed Web of Science ®Google Scholar
• Bakker NP, van Erck MG, Zurcher C, Faaber P, Lemmens A, Hazenberg M, et al. Experimental immune mediated arthritis in rhesus monkeys. A model for human rheumatoid arthritis?. Rheumatol Int 1990; 10:21 - 29
   PubMed Web of Science ®Google Scholar
• t'Hart BA, Amor S, Jonker M. Evaluating the validity of animal models for research into therapies for immune-based disorders. Drug Discov Today 2004; 9:517 - 524
   PubMed Web of Science ®Google Scholar
• Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003; 9:540 - 549
   PubMed Web of Science ®Google Scholar
• Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers 2006; 22:235 - 244
   PubMed Web of Science ®Google Scholar
• Muller D, Trunk G, Sichelstiel A, Zettlitz KA, Quintanilla M, Kontermann RE. Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice. J Immunol Methods 2008; 339:90 - 98
   PubMed Web of Science ®Google Scholar
• Muller D, Karle A, Meissburger B, Hofig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007; 282:12650 - 12660
   PubMed Web of Science ®Google Scholar
• Myszka DG, Morton TA. CLAMP: a biosensor kinetic data analysis program. Trends Biochem Sci 1998; 23:149 - 150
   PubMed Web of Science ®Google Scholar
• Myszka DG. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Curr Opin Biotechnol 1997; 8:50 - 57
   PubMed Web of Science ®Google Scholar
• Benedict CA, MacKrell AJ, Anderson WF. Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. J Immunol Methods 1997; 201:223 - 231
   PubMed Web of Science ®Google Scholar